ライフサイエンスコーパス: TGF-beta type II receptor

1 containing the extracellular portion of the TGF-beta type II receptor.

2 o TRIP-1, a phosphorylation substrate of the TGF-beta type II receptor.

3 lines lacking either DPC4 expression or the TGF-beta type II receptor.

4 the p53 and Rb genes, but requires an intact TGF-beta type II receptor.

5 e is dependent on the kinase activity of the TGF-beta type II receptor.

6 th a retrovirus containing dominant-negative TGF-beta type II receptor.

7 F by TGF-beta1 can be blocked by antibody to TGF-beta type II receptors.

8 ach of these lines, except those that lacked TGF-beta type II receptors.

9 ant adenovirus expressing a secreted form of TGF-beta type II receptor (Ad5-RIIs), an adenovirus expr

10 iggered, as evidenced by upregulation of the TGF-beta type II receptor and activation of the downstre

11 n that has the ability to associate with the TGF-beta type II receptor and is phosphorylated by it (1

12 We evaluated the expression of TGF-beta type II receptor and pSmad2 immunohistochemical

13 SNU638 cells that contain a mutation in the TGF-beta type II receptor and SNU484 cells that express

14 ibited by co-transfection with a kinase dead TGF-beta type II receptor and that constitutive activati

15 etic (overexpression of sTbetaRII, a soluble TGF-beta type II receptor) and pharmacologic (1D11, a TG

16 ling by downregulating the expression of the TGF-beta type II receptor, and its signaling intermediat

17 and expression of the TGF-beta1 isoform, the TGF-beta type II receptor, and the Smad signaling pathwa

18 r kinase inhibitor LY2157299, a neutralizing TGF-beta type II receptor antibody, and SMAD4 siRNA all

19 epithelium was increased in the presence of TGF-beta type II receptor antisense oligodeoxynucleotide

20 ls in control embryonic lung explants, while TGF-beta type II receptor antisense oligodeoxynucleotide

21 TGF-beta type II receptor appears to bind only TGF-beta,

22 is caused by mutations in BMPR2, encoding a TGF-beta type II receptor (BMPR-II).

23 ory to this effect, expressing low levels of TGF-beta type II receptors compared with peripheral bloo

24 Consistent with this observation, TGF-beta type II receptor deletion in cultured collectin

25 anisms: (i) cellular uptake of TGF-beta by a TGF-beta type II receptor-dependent mechanism and (ii) r

26 rexpress a dominant-negative mutation of the TGF-beta type II receptor (DNIIR) under the control of a

27 mice harboring the dominant-negative mutant TGF-beta type II receptor (DNTGF beta RII) in mouse epit

28 ice, the conditional stromal knockout of the TGF-beta type II receptor expression (Tgfbr2(fspKO)) res

29 hing similar to that caused by inhibition of TGF-beta type II receptor expression and signaling.

30 , these results show for the first time that TGF-beta type II receptor expression can be controlled b

31 The cytoplasmic pattern of TGF-beta type II receptor expression in cancer cells was

32 In conclusion, the frequent loss of stromal TGF-beta type II receptor expression in human prostate c

33 Dominant negative TGF-beta type II receptor expression inhibited TGF-beta

34 Thus, abrogation of TGF-beta type II receptor expression prevented TGF-beta1

35 We tested the impact of a soluble TGF-beta type II receptor extracellular domain expressed

36 nucleotide inhibitory strategies to abrogate TGF-beta type II receptor function in embryonic mouse lu

37 Thus, we studied the effect of a soluble Fc:TGF-beta type II receptor fusion protein (Fc:TbetaRII) o

38 ve previously shown that the deletion of the TGF-beta type II receptor gene (Tgfbr2) expression in my

39 eta (TGF-beta) signaling in mice lacking the TGF-beta type II receptor gene (Tgfbr2) in their limbs (

40 ated mice with a conditional deletion of the TGF-beta type II receptor gene (Tgfbr2) specifically in

41 signaling in liver regeneration in vivo, the TGF-beta type II receptor gene (Tgfbr2) was selectively

42 Somatic alterations of the TGF-beta type II receptor gene (TGFBR2) were identified

43 etermined by conditional inactivation of the TGF-beta type II receptor gene in mouse fibroblasts (Tgf

44 origenesis, we conditionally knocked out the TGF-beta type II receptor gene in mouse mammary fibrobla

45 nature to directly test this hypothesis: the TGF-beta type II receptor gene is inactivated by mutatio

46 ctive assay to detect instability within the TGF-beta Type II receptor gene.

47 irus vector expressing the dominant-negative TGF-beta type II receptor HATGF-betaRII-Deltacyt.

48 t overcome the stimulatory effects either of TGF-beta type II receptor immunoperturbation or of antis

49 Expression of a dominant-negative TGF-beta type II receptor in cells that over-expressed e

50 s also have implications for the role of the TGF-beta type II receptor in disease, as tumor cells har

51 sponse to injury by selectively deleting the TGF-beta type II receptor in mice at the initiation of u

52 eshift mutations of the poly(A) tract of the TGF-beta type II receptor in replication error-positive

53 xpressing a dominant-negative mutant form of TGF-beta type II receptor in the pancreas, under control

54 response to AKI, we selectively deleted the TGF-beta type II receptor in the proximal tubules of mic

55 form of the transforming growth factor beta (TGF-beta) type II receptor in skeletal tissue resulted i

56 the role of transforming growth factor-beta (TGF-beta) type II receptor in the TGF-beta-dependent pro

57 al inactivation of Tgfbr2, which encodes the TGF-beta type II receptor, in smooth muscle cells of pos

58 the surrounding mesenchyme, indicating that TGF-beta type II receptor is an important regulator of e

59 Thus, TbetaRI, like the TGF-beta type II receptor, is a dual-specificity kinase.

60 n (TRIP-1) is a cytoplasmic substrate of the TGF-beta type II receptor kinase and plays a role in TGF

61 hers to be an intracellular substrate of the TGF-beta type II receptor kinase which plays an importan

62 de is phosphorylated by only TbetaRI and not TGF-beta type-II receptor kinase, indicating that the pe

63 el, inducible, conditional, and fibroblastic TGF-beta type II receptor knockout (Tgfbr2(dermalKO)) mo

64 which is reminiscent of BMP-4, TGF-beta1 and TGF-beta type II receptor knockout mice.

65 e response to androgen ablation, conditional TGF-beta type II receptor knockout mouse models of the e

66 hybridization and immunohistochemistry, both TGF-beta type II receptor mRNA and protein were localize

67 ss of ERT expression, leading to the loss of TGF-beta type II receptor mRNA in human gastric cancer c

68 bled and mismatched sequence controls, while TGF-beta, type II receptor mRNA and its protein expressi

69 TGF-beta type II receptor mutation (DR26Delta25), which

70 eceptor in disease, as tumor cells harboring TGF-beta type II receptor mutations exhibit impaired TGF

71 Antisera directed against a TGF-beta type II receptor N-terminal peptide that pertur

72 Similarly, antisense TGF-beta type II receptor oligodeoxynucleotides (40 micr

73 ice or mice expressing the dominant negative TGF-beta type II receptor on TECs, TGF-beta was shown to

74 There was similar expression of TGF-beta type II receptors on both CLL B cells and norma

75 In vitro, deficiency of the TGF-beta type II receptor protected proximal tubule epit

76 A reduction in the autophosphorylation the TGF-beta type II receptor protein, a constitutively acti

77 Indeed, 786-O cells were found to express no TGF-beta type II receptor protein, thus allowing them to

78 um of plasmid expressing a dominant-negative TGF-beta type II receptor (pUBc-TGFbeta-DN-RII; n=9) or

79 Despite recent progress, the regulation of TGF-beta type II receptor remains uncertain.

80 nt-negative mutant (TbetaRIIDeltacyt) of the TGF-beta type II receptor rendered the human breast canc

81 athway or pretreatment with soluble chimeric TGF-beta type II receptor restored beta(2)-adrenergic re

82 Smad3, adenomatous polyposis coli (APC), or TGF-beta type II receptor) restored the TGF-beta antipro

83 ion and immunohistochemical staining for the TGF-beta type II receptor revealed concordant and signif

84 vious work has shown that loss of functional TGF-beta type II receptor (RII) due to a frameshift muta

85 Transcriptional repression of the TGF-beta type II receptor (RII) is one of the mechanisms

86 ansforming growth factor (TGF)-beta and that TGF-beta type II receptor (RII) mutations are found in H

87 Recent studies have identified TGF-beta type II receptor (RII) mutations in a subset of

88 TGF-beta correlates with inactivation of the TGF-beta type II receptor (RII).

89 beta signaling by altering the expression of TGF-beta type II receptor (RII).

90 beta) because of a lack of expression of the TGF-beta type II receptor (RII).

91 6 that lack transforming growth factor beta (TGF-beta) type II receptor (RII) demonstrated restoratio

92 her lack of transforming growth factor beta (TGF-beta) type II receptor (RII) expression and loss of

93 The transforming growth factor-beta (TGF-beta) type II receptor (RII) is a colon cancer suppr

94 ucts of the transforming growth factor-beta (TGF-beta) type II receptor (RII) promoter linked to the

95 ng mice overexpressing the dominant-negative TGF-beta type II receptor showed an increase in endocrin

96 GF-beta1 binding molecule, the soluble human TGF-beta type II receptor (sTbetaRII.Fc), in the treatme

97 , for the first time, that abrogation of the TGF-beta type II receptor stimulates embryonic lung orga

98 GF-beta binding was inhibited with a soluble TGF-beta type II receptor (STR) construct, administered

99 can be maintained in cells with inactivated TGF-beta type II receptors, suggesting the persistence o

100 The transforming growth factor-beta (TGF beta) type II receptor (T beta R-II) is responsible

101 resulted from UV-induced down-regulation of TGF-beta type II receptor (T beta RII) mRNA and protein.

102 ediated gene transfer of a dominant negative TGF-beta type II receptor targeting murine bone marrow.

103 In many cancers, expression of TGF-beta type II receptor (TbetaR-II) is markedly decrea

104 whether in vivo administration of a soluble TGF-beta type II receptor (TbetaR-II) protein ameliorate

105 a(3) integrin interacted physically with the TGF-beta type II receptor (TbetaR-II), leading to its ty

106 e are reminiscent of mice lacking TGF-beta1, TGF-beta type II receptor (TbetaR-II), or endoglin, sugg

107 n as TGF-beta type I receptor (TbetaR-I) and TGF-beta type II receptor (TbetaR-II).

108 vels of the transforming growth factor-beta (TGF-beta) Type II receptor (TbetaR-2) and are functional

109 verexpression of transforming growth factor (TGF) beta type II receptor (TbetaRII) gene in human pros

110 d that in human BCa bone metastatic tissues, TGF-beta type II receptor (TbetaRII) and p-Smad2 were ex

111 y direct and specific molecular targeting of TGF-beta type II receptor (TbetaRII) and Smad7 in retina

112 sion lymphoma through down-regulation of the TGF-beta type II receptor (TbetaRII) by epigenetic mecha

113 Tesseur et al. report that the expression of TGF-beta type II receptor (TbetaRII) by neurons is reduc

114 lls, as well as in endothelial cell-specific TGF-beta type II receptor (TbetaRII) conditional mutants

115 In particular, knockout of the TGF-beta type II receptor (TbetaRII) in nestin-positive

116 We report that the TGF-beta type II receptor (TbetaRII) is mainly expressed

117 ations have suggested that repression of the TGF-beta type II receptor (TbetaRII) may be an important

118 For example, in addition to mutations in TGF-beta type II receptor (TbetaRII) that abrogate norma

119 eceptor required for TGF-beta signaling, the TGF-beta type II receptor (TbetaRII), as an alternative

120 have differential binding affinities for the TGF-beta type II receptor (TbetaRII).

121 ants inhibit TGF-beta signaling by targeting TGF-beta type II receptor (TbetaRII).

122 Smad3 and to decrease cytosolic and membrane TGF-beta type II receptor (TbetaRII).

123 pathway in human skin by down-regulation of TGF-beta type II receptor (TbetaRII).

124 there are no known direct modulators for the TGF-beta type II receptor (TbetaRII).

125 TGF-beta1 in the PCT binds to intracellular TGF-beta type II receptor (TbetaRII).

126 inhibited by the TGF-beta inhibitor-soluble TGF-beta type II receptor (TbetaRII:Fc), suggesting they

127 sion of the transforming growth factor-beta (TGF-beta) type II receptor (TbetaRII) gene is one of sev

128 Mice lacking the TGF-beta-type-II-receptor (TbetaRII) in their limbs (Tgf

129 e marrow (BM) expressing a dominant-negative TGF-beta type II receptor (TbetaRIIDN) leads to the gene

130 tracts present in the coding sequence of the TGF beta type II receptor (TGF beta IIR) and Bax implies

131 eta1 but exhibit decreased expression of the TGF-beta type II receptor (TGF-(beta)RII).

132 simultaneously with decreased expression of TGF-beta type II receptor (TGF-beta RII) mRNA and protei

133 SF mRNA expression levels for TGF-beta1, TGF-beta type II receptor (TGF-beta RII), thrombospondin

134 We examined TGF-beta, TGF-beta type II receptor (TGF-beta-RII), and p27 expres

135 er fibrosis, we generated adult mice lacking TGF-beta type II receptor (TGF-betaIIR) from the liver.

136 wn that the transforming growth factor beta (TGF-beta) type II receptor (TGF-beta RII), a putative tu

137 regulate expression of TGFBR2 (encoding the TGF-beta type II receptor, TGF-beta RII; Refs 9,14), a p

138 ts seen in corresponding mutants lacking the TGF-beta type II receptor (TGFbetaRII), a prototypical b

139 stromal cells from Tgfbr2(fspKO) and floxed TGF-beta type II receptor Tgfbr2(floxE2/floxE2) mice on

140 a member of the transforming growth factor (TGF)-beta type II receptor (TGFBR2) family and controls

141 Previously, we showed that deletion of the TGF-beta type II receptor (Tgfbr2) in Type II Collagen (

142 se of the 10-bp polyadenine tract within the TGF-beta type II receptor (TGFBR2), a well-characterized

143 , which is often inactivated by mutations of TGF-beta type II receptor (TGFBR2).

144 ibroblasts conditionally knocked out for the TGF-beta type II receptor (Tgfbr2-KO) resulted in larger

145 Double visualization of TGF-beta type II receptor (TGFRII) and TUNEL reactivity

146 dose by depleting TGF-beta via constitutive TGF-beta type II receptor trafficking processes.

147 sgenic mice that express a dominant-negative TGF-beta type II receptor under control of the metalloth

148 GF-beta type I receptor or dominant negative TGF-beta type II receptor under control of the mouse mam

149 gnaling by expression of a dominant-negative TGF-beta type II receptor, use of a TGF-beta type I rece

150 Finally, when antibody to TGF-beta type II receptor was added before TGF-beta1 tre

151 cytoplasmically truncated dominant negative TGF-beta type II receptor, we blocked TGF-beta-mediated

152 study, we examine and compare the defects of TGF-beta type II receptor (Wnt1-Cre;Tgfbr2(fl/fl)) and T